Stratigos AJ, Sekulic A, Peris K, et al. - Researchers report the primary analysis data of cemiplimab, a PD-1 antibody, in patients suffering from locally advanced basal cell carcinoma following hedgehog inhibitor (HHI) therapy. In an open-label, multicentre, single-arm, phase 2 trial, eligible patients were treated with cemiplimab 350 mg intravenously every 3 weeks for up to 93 weeks or until progression or unacceptable toxicity. Findings demonstrated clinically meaningful antitumour activity of cemiplimab, along with its acceptable safety profile, in patients suffering from locally advanced basal cell carcinoma post-HHI therapy.